[
  {
    "ts": null,
    "headline": "Franklin Biotechnology Discovery Fund Q2 2025 Commentary",
    "summary": "Franklin Templetonâs Biotechnology Discovery Fund sees long-term potential despite Q2 losses. Explore how innovation and AI are shaping its outlook.",
    "url": "https://finnhub.io/api/news?id=d61632bb7ac932a66ab21f6c57260f4bb79e88518f44428ce4f279a1392e761e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753997700,
      "headline": "Franklin Biotechnology Discovery Fund Q2 2025 Commentary",
      "id": 136159393,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1408826216/image_1408826216.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Franklin Templetonâs Biotechnology Discovery Fund sees long-term potential despite Q2 losses. Explore how innovation and AI are shaping its outlook.",
      "url": "https://finnhub.io/api/news?id=d61632bb7ac932a66ab21f6c57260f4bb79e88518f44428ce4f279a1392e761e"
    }
  },
  {
    "ts": null,
    "headline": "Trump Talks Tough on Drug Prices but His Demands Have Softened",
    "summary": "The president threatened to “deploy every tool” in the administration’s arsenal if drug companies don’t cut certain prices by late September.",
    "url": "https://finnhub.io/api/news?id=abfd0cbc3bdf5cf7eec493e57c4c23222429aa6d3fbd91ae1cf65b8720b77b7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753997100,
      "headline": "Trump Talks Tough on Drug Prices but His Demands Have Softened",
      "id": 136160929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The president threatened to “deploy every tool” in the administration’s arsenal if drug companies don’t cut certain prices by late September.",
      "url": "https://finnhub.io/api/news?id=abfd0cbc3bdf5cf7eec493e57c4c23222429aa6d3fbd91ae1cf65b8720b77b7a"
    }
  },
  {
    "ts": null,
    "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
    "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753992991,
      "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
      "id": 136160870,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18"
    }
  },
  {
    "ts": null,
    "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
    "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
    "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753986626,
      "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
      "id": 136160873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
      "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64"
    }
  },
  {
    "ts": null,
    "headline": "Trump pressures 17 pharma CEOs to cut US drug prices",
    "summary": "WASHINGTON (Reuters) -President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday.  Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas.  Trump sent the letters to the chief executives of Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson, and AstraZeneca, among others, the White House said.",
    "url": "https://finnhub.io/api/news?id=42f946e05257529f3d2dad4cf4341c0643378e0fd5f4f914bc3d4cd3e3e1295a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753986479,
      "headline": "Trump pressures 17 pharma CEOs to cut US drug prices",
      "id": 136160874,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "WASHINGTON (Reuters) -President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said on Thursday.  Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas.  Trump sent the letters to the chief executives of Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson, and AstraZeneca, among others, the White House said.",
      "url": "https://finnhub.io/api/news?id=42f946e05257529f3d2dad4cf4341c0643378e0fd5f4f914bc3d4cd3e3e1295a"
    }
  },
  {
    "ts": null,
    "headline": "Trump demands largest pharma companies slash US drug prices",
    "summary": "(Bloomberg) -- President Donald Trump sent letters to 17 of the world’s largest pharmaceutical companies — including Eli Lilly & Co., Novo Nordisk A/S and Pfizer Inc. — insisting they slash their US prices on new drugs to the lowest amount paid by certain other countries.Most Read from BloombergThe World’s Data Center Capital Has Residents SurroundedAn Abandoned Art-Deco Landmark in Buffalo Awaits RevivalWe Should All Be Biking Along the BeachBudapest’s Most Historic Site Gets a Controversial Re",
    "url": "https://finnhub.io/api/news?id=292aa5d0e8c41af62ddead7ad247376e84410f5a02b83d2a1a0bbf469f796efb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753985112,
      "headline": "Trump demands largest pharma companies slash US drug prices",
      "id": 136160875,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- President Donald Trump sent letters to 17 of the world’s largest pharmaceutical companies — including Eli Lilly & Co., Novo Nordisk A/S and Pfizer Inc. — insisting they slash their US prices on new drugs to the lowest amount paid by certain other countries.Most Read from BloombergThe World’s Data Center Capital Has Residents SurroundedAn Abandoned Art-Deco Landmark in Buffalo Awaits RevivalWe Should All Be Biking Along the BeachBudapest’s Most Historic Site Gets a Controversial Re",
      "url": "https://finnhub.io/api/news?id=292aa5d0e8c41af62ddead7ad247376e84410f5a02b83d2a1a0bbf469f796efb"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=8c7342f27e498057852f38b7dac17b7615120b7fc9f379e941b99894eacdec58",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753980360,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "id": 136223708,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=8c7342f27e498057852f38b7dac17b7615120b7fc9f379e941b99894eacdec58"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down",
    "summary": "SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.",
    "url": "https://finnhub.io/api/news?id=6ec3e72c633eb9690163502a9f22201fae861ca16854e3e1916d1b94ae4a18fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753972620,
      "headline": "Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down",
      "id": 136155402,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "SNY misses Q2 earnings and sales estimates but lifts 2025 sales outlook on strong Dupixent and vaccine momentum.",
      "url": "https://finnhub.io/api/news?id=6ec3e72c633eb9690163502a9f22201fae861ca16854e3e1916d1b94ae4a18fd"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "0815 GMT – Sanofi’s higher costs overshadow an upgrade to its full-year guidance, Intron Health’s Naresh Chouhan and Dominic Rose say in a research note.  Sales at the French pharmaceutical company beat expectations, but its earnings came in weaker than expected due to higher costs and currency headwinds, Intron says.  Sanofi’s business operating profit missed consensus expectations by 4%, Intron says.",
    "url": "https://finnhub.io/api/news?id=ff6003e01792e240f8199134174e4341dca62ed2b7c045560fbe3581c9a4ee64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753966860,
      "headline": "Health Care Roundup: Market Talk",
      "id": 136154426,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "0815 GMT – Sanofi’s higher costs overshadow an upgrade to its full-year guidance, Intron Health’s Naresh Chouhan and Dominic Rose say in a research note.  Sales at the French pharmaceutical company beat expectations, but its earnings came in weaker than expected due to higher costs and currency headwinds, Intron says.  Sanofi’s business operating profit missed consensus expectations by 4%, Intron says.",
      "url": "https://finnhub.io/api/news?id=ff6003e01792e240f8199134174e4341dca62ed2b7c045560fbe3581c9a4ee64"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (REGN) Q2 Earnings: What To Expect",
    "summary": "Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know.",
    "url": "https://finnhub.io/api/news?id=d07171ff9c18ed6ed1bfa4fcfe7bef775cbdf02c592c0168c58094cd924dee57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753930897,
      "headline": "Regeneron (REGN) Q2 Earnings: What To Expect",
      "id": 136149392,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know.",
      "url": "https://finnhub.io/api/news?id=d07171ff9c18ed6ed1bfa4fcfe7bef775cbdf02c592c0168c58094cd924dee57"
    }
  }
]